Dear Colleague,
Welcome to the 1st EACMT Symposium for expert practitioners. The symposium is organized in collaboration with Erasmus Medical Centre which is a top European research-based and innovation institutes Thrombosis remains the major cause of morbidity and mortality in AF patients and the elderly. For decades, Warfarin was the cornerstone to prevent Stroke and Systemic Embolism (SSE).
Nevertheless, it was not free of complications due to its low therapeutic index and the difficulty of reaching the delicate balance between thrombosis and bleeding. The advent of the novel Direct Oral Anti Coagulants (DOACs) revolutionized our understanding of the pathophysiology and the management in different categories of patients including those with concomitant conditions, chronic kidney diseases, woman and frail patients as well as pulmonary embolism and venous thromboembolism.
This Symposium highlights the important new data which has relevance to outcomes and treatment strategies. The role of new therapeutic advances, such as VTE and cancer, antithrombotic treatment in ACS, post-stroke, and valvular diseases, is also addressed.
The role of key classes of drugs, and new methods of diagnosis and treatment, will be considered.
Despite the explosion of new knowledge, treatment in clinical practice often falls short of evidence-based recommendations and real-world data. A primary educational objective of this meeting will be to discuss clinical trials and real-world data and develop a consensus on practical approaches to improve day-to-day management of individuals at risk from or with clinical problems of thrombosis in AF patients or venous thromboembolic events.
We hope that the Symposium will provide an exciting forum for the review, exchange and assimilation of findings from clinical trials, real-world data, consensus, guidelines and best practices to improve the clinical practice. We wish you an enjoyable and fruitful stay in Rotterdam.
Yours sincerely,
Professor Freek W.A. Verheugt
Symposium Chairman